Aspirin sensitivity in diabetes mellitus; the role of glycaemic control and dosing
Phase 4
- Conditions
- diabetes mellitusType 2 diabetes100110821001265310003216
- Registration Number
- NL-OMON31925
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 140
Inclusion Criteria
Age > 18 years
Diagnosis of type 2 diabetes according to ADA criteria
Exclusion Criteria
Current acetylsalicylic acid therapy
Use of any medication interfering with platelet function, e.g. diclofenac, naproxen or clopidogrel
Allergy or hypersensitivity to prostaglandinsynthetase inhibitors
Hemorrhagic stroke in medical history
Gastric complaints or gastritis/ulcus pepticum
Severe liver or kidneyfailure
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main study parameter is the prevalence of laboratory acetylsalicylic acid<br /><br>resistance in patients stratified by level of glycaemic control. </p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary endpoint is the ability of increased dosing to overcome<br /><br>hyperglycaemia-associated acetylsalicylic acid resistance.</p><br>